Division of Liver Diseases, Mount Sinai School of Medicine, Box 1104, One Gustave L Levy Place, New York, NY 10029-6574 USA.
Hepatol Int. 2010 Oct 24;5(1):597-602. doi: 10.1007/s12072-010-9218-y.
Hemophagocytic syndrome is a potentially fatal complication that rarely occurs after liver transplantation. We present a 25-year-old man with a history of Still's disease who presented with fever, arthralgia, and elevated serum ferritin levels 6 months after undergoing liver transplantation for fulminant hepatic failure due to autoimmune hepatitis potentially triggered by infliximab therapy. Liver biopsy demonstrated features consistent with hemophagocytic syndrome. The patient was successfully treated with a course of high dose steroids and had complete resolution of his symptoms and normalization of liver chemistry test abnormalities. Patients with Still's disease may rarely complicate with fulminant hepatic failure with infliximab therapy. Hemophagocytic syndrome a rare potentially life threatening condition may occur in such patients following liver transplantation.
噬血细胞综合征是肝移植后罕见的致命并发症。我们报告了 1 例 25 岁男性，有斯蒂尔病病史，在因自身免疫性肝炎导致暴发性肝衰竭行肝移植后 6 个月时出现发热、关节痛和血清铁蛋白水平升高。肝脏活检显示符合噬血细胞综合征的特征。患者接受了大剂量类固醇治疗，症状完全缓解，肝功能试验异常恢复正常。斯蒂尔病患者在接受英夫利昔单抗治疗时可能很少会并发暴发性肝衰竭。噬血细胞综合征是一种罕见的潜在危及生命的疾病，在这些患者肝移植后可能会发生。
